Allergies Immune Response In-Vivo Medicine 
The Pharma Data
JULY 8, 2021
The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.(1) Results from the NAVIGATOR Phase 3 trial were published in the New England Journal of Medicine in May 2021.
The Pharma Data
APRIL 27, 2021
General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Progress on implementation of the Corporate Social Responsibility strategy. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4%
Expert insights. Personalized for you.
52 
Let's personalize your content